To include your compound in the COVID-19 Resource Center, submit it here.

How GSK has rebuilt its oncology pipeline from the ground up

Two years into its cancer rebuild, GSK's strategy to break into immuno-oncology may soon start to pay off

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two compounds about to test their place in the oncology market.

While the pharma’s near-term growth in the therapeutic area hangs on the outcome of the BCMA race, it has been broadening its pipeline with assets spanning checkpoint inhibitors to cell therapies to secure a long-term position in an arena that almost left it behind.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has rebuilt its cancer pipeline from 11 early stage assets in 2015, when the company sold off its entire commercial cancer portfolio, to a stocked pipeline of seven Phase II and III programs, nine earlier stage candidates and one marketed drug (see Figure: “GSK’s Oncology Pipeline”).

The company is teeing up three regulatory filings for the end of this year: one for its BCMA antibody-drug conjugate (ADC) belantamab mafodotin (GSK2857916) in fourth-line multiple myeloma (MM), one for its anti-PD-1 mAb dostarlimab in endometrial cancer, and the third to expand the label of its single marketed oncology therapy, PARP inhibitor Zejula niraparib, to include first-line ovarian cancer.

Each stands to boost the company's meager oncology sales -- Zejula brought in £57 million ($72.08 million) in the second quarter of this year -- but the BCMA ADC stands to make the biggest impact if it can garner a sizable share of the multi-billion dollar myeloma market.

The other two filings are more strategic, intended to squeeze extra value out of Zejula and support future combination regimens.

“My CEO has

Read the full 2684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers